相关临床试验
349
106 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1909
进行中（未招募）
24
6.9%
已完成
126
36.1%
尚未招募
82
23.5%
招募中
86
24.6%
暂停
1
0.3%
终止
15
4.3%
Unknown
9
2.6%
撤回
6
1.7%
暂无批准数据
- Terumo Corporation has launched VenoJect II RAPClot blood collection tubes in Japan, featuring Q-Sera's patented technology derived from snake venom proteins. - The innovative tubes reduce serum processing time to just five minutes, even from anticoagulated blood, representing the first major innovation in blood collection in decades. - Q-Sera is now seeking global partnerships to expand the RAPClot technology beyond Japan, potentially transforming laboratory diagnostics worldwide. - The technology uses recombinant ecarin proteins originally identified from snake venom to accelerate blood clotting and improve diagnostic accuracy.
- The GAME CHANGER trial demonstrated that cefiderocol was non-inferior to standard antibiotic therapy for treating hospital-acquired and healthcare-associated Gram-negative bloodstream infections, with 14-day mortality rates of 8% versus 7% respectively. - Among patients with carbapenem-resistant infections, cefiderocol showed comparable efficacy with mortality rates of 14% compared to 10% for standard therapy, though it did not achieve superiority. - Safety analysis revealed five treatment-related serious adverse events exclusively in the cefiderocol group, including delirium and abnormal liver chemistry, all of which resolved with minimal intervention. - The findings establish cefiderocol as a viable therapeutic option for severe Gram-negative infections, particularly important given the limited treatment options for carbapenem-resistant pathogens.
- INOVIQ has licensed exclusive worldwide rights to novel exosomal biomarker intellectual property from The University of Queensland to enhance its EXO-OC ovarian cancer screening test. - The EXO-OC test demonstrated 100% sensitivity for early-stage ovarian cancer detection and 99.6% specificity in a 500-sample blind study, addressing a critical unmet need in oncology. - The company plans to launch EXO-OC as a Laboratory Developed Test in the US by late 2026, with commercial discussions already underway with major clinical laboratories. - Financial terms include A$25,000 upfront, up to A$360,000 in milestones, and tiered royalties up to 2.5% on net sales, securing exclusive rights for at least ten years.
- Brisbane-based Ceretas received a $2.4 million grant from Australia's Medical Research Future Fund to accelerate development of its therapeutic ultrasound device for Alzheimer's treatment. - The device uses focused ultrasound neuromodulation to non-invasively stimulate brain regions linked to memory and cognition, targeting deeper areas without surgery or recovery time. - The technology can temporarily open the blood-brain barrier to help clear amyloid plaques and tau tangles while potentially improving drug delivery to the brain. - Ceretas licensed the ultrasound technology from The University of Queensland in 2024, following approximately $20 million in research development over the past decade.
- Sanofi announced plans to acquire London-based biotechnology company Vicebio for $1.15 billion in cash, with potential milestone payments up to $450 million based on development achievements. - The acquisition brings Vicebio's proprietary Molecular Clamp technology that stabilizes viral proteins and enables development of fully liquid combination vaccines stored at standard refrigeration temperatures. - Vicebio's pipeline includes VXB-241, a bivalent vaccine candidate targeting RSV and hMPV currently in phase 1 trials, and VXB-251, a preclinical trivalent vaccine candidate. - The transaction is expected to close in Q4 2025 and will expand Sanofi's respiratory vaccines capabilities beyond its existing flu and RSV prevention portfolio.
- A groundbreaking radioactive therapy targeting the CDCP1 protein in cancer cells has begun its first human trial in Australia, with a 69-year-old Brisbane woman becoming the first patient to receive the treatment. - The therapy, developed over 24 years by Professor John Hooper, uses an innovative antibody that binds to CDCP1 found in ovarian, bladder, and other common cancers to deliver targeted radiotherapy. - Up to 45 patients with ovarian and bladder cancer will participate in the trial, which aims to provide exceptionally accurate imaging of metastasizing cancer and potentially become the gold standard treatment for multiple cancer types. - The research represents a collaboration between Mater Research, The University of Queensland, CSIRO, and other institutions, with ovarian cancer having a five-year survival rate of just 49 percent.
- University of Queensland researchers have identified DS90, the first nanobody capable of neutralizing both Nipah and Hendra viruses, for which no approved vaccines or cures currently exist. - The nanobody, derived from alpaca immune cells, can access deep viral pockets that traditional antibodies cannot reach and successfully blocks viral entry into cells. - Combining DS90 with existing m102.4 antibody therapy prevents Nipah virus from mutating and evolving, offering a powerful strategy to prevent deadly variants from emerging. - The discovery represents a crucial step toward developing clinical treatments for these fatal respiratory and neurological diseases that cause regular outbreaks in Asia and Australia.
- A one-year clinical trial demonstrated that triheptanoin, a liquid fat supplement, can reverse mitochondrial dysfunction and cell death in patients with Ataxia-telangiectasia (A-T), a rare degenerative disease affecting 1 in 100,000-300,000 people in Australia. - The study enrolled 31 A-T patients aged 4-37 years and showed significant improvements in quality of life, including better feeding ability, improved speech intelligibility, and reduced fatigue levels that allowed children to participate more fully in school and family activities. - Researchers identified two key biomarkers for monitoring disease progression and found that combining triheptanoin with nicotinamide riboside (vitamin B3) reduced cell death, leading to plans for an international clinical trial testing this dual treatment approach.
- Australian researchers at The University of Queensland have dosed the first five participants in a groundbreaking clinical trial of ASITI-201, an immunotherapy designed to rebalance immune response in Type 1 diabetes. - The novel treatment combines pancreatic protein fragments with vitamin D to prevent immune attacks on insulin-producing cells, potentially preserving pancreatic function and reducing insulin dependence in recently diagnosed patients. - If successful, the therapy could fundamentally change treatment approaches by addressing the root cause of Type 1 diabetes, with future applications potentially including prevention in high-risk individuals and adaptation for other autoimmune conditions.
- The University of Queensland is launching a clinical trial of a novel blood test that has shown 94% accuracy in detecting early-stage ovarian cancer, potentially revolutionizing screening for this deadly disease. - The innovative screening method targets extracellular vesicles and boasts a remarkably low false-positive rate of 4%, making it highly suitable for population-based screening programs. - The study will recruit 1,500 postmenopausal women across Queensland to validate the test's performance under real-world conditions, supported by major research foundations.
